



Next Generation MRgHIFU

Using Ultrasound technology, EpiSonica creates cutting-edge, precision medical devices, to fulfil enormous unmet medical needs

Non-invasive | No incision | No radiation | Clear MR image



The ArcBlate MRgHIFU System Innovation

Patented Arc Design

- ✔ Portable, easily mounted onto the MRI Bed
- ✔ Top mounted transducer with water bag closely contact with patient's skin surface reduces the risk of skin burn
- ✔ Transducer moves along 3D-axes offers wider angle of operation for precise positioning

Combined with MRI

- ✔ **Precise anatomy image guiding**
Precisely target lesion to avoid high risk area ensuring safety
- ✔ **Real-time thermal monitoring**
Continuous temperature monitoring during treatment and confirm the efficacy of thermal ablation and avoid over-treatment



Clinical Applications

ArcBlate MRgHIFU offers non-invasive thermal ablation for soft tissues to treat benign tumors including uterine fibroids, adenomyosis at current. It will also be applied for pain palliation of bone metastases, pancreatic cancer as well in the near future.

The setting is also suitable to explore other treatments for symptom relief of inoperable abdominal tumors, such as liver cancer, bladder cancer, etc.



FIRST STAGE



**Uterine Fibroids
Adenomyosis**

I



**Bone
Metastases**

II

SECOND STAGE



**Pancreatic
cancer**

III



**Liver
cancer**

IV




Clinical Advantages

- ✔ Non-invasive treatment with No Incision, No Bleeding and No Radiation
- ✔ Outpatient procedure with rapid recovery to normal living conditions
- ✔ Conscious sedation only, general anesthesia free


Value For Healthcare Providers

- ✔ Real-time MRI/thermal monitoring for maximum safety and precision therapy
- ✔ Repeatable radiation-free treatment if needed.
- ✔ Efficient MR utilization: easily upgrade diagnostic MR scanner to therapeutic practice with MRgHIFU
- ✔ Reduce patient length of hospital stays and associated costs


Clinical Cases - uterine fibroids



Before treatment



1 month after treatment, volume shrunk by 25%



6 month after treatment, volume shrunk by 45%